Verrica Pharmaceuticals Inc.
VRCAHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeVerrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States. The $93.5M market capitalization puts VRCA squarely in micro-cap range for its industry. The company offers YCANTH (VP-102) a drug-device combination that contains a GMP-controlled formulation of cantharidin for the treatment of molluscum in adult and pediatric patients, as well as for the treatment of common warts.
Market Cap
$93.5M
Beta
1.48
P/E (TTM)
—
P/E (Fwd)
-4.38
EPS (TTM)
$-1.08
EPS (Fwd)
$-1.24
ROE
—
ROA
-20.9%
Cash
$20.6M
Total Debt
$1.4M
Free CF
-$12.2M
52W Change
-24.6%
Annual Financials
Cash vs Debt
Where VRCA stands vs its 150-day and 200-day moving averages
As of the July 15, 2026 close, VRCA finished 9.19% below its 150-day moving average ($6.53) and 1.50% below its 200-day moving average ($6.02). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is VRCA overbought or oversold?
At the July 15, 2026 close, VRCA's RSI(14) was 53.9, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Verrica Pharmaceuticals Inc. holds $20.6M in cash against $1.4M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company is burning cash, with free cash flow at -$12.2M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Revenue has grown from $9.0M (2022) to $35.6M (2025), reflecting a 294% increase over the period.
With cash comfortably exceeding debt, VRCA has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing VRCA.